|
UroToday / GU OncToday is pleased to introduce Science in GU Oncology with Bishoy M. Faltas, MD, a new monthly expert-led column offering clinicians and researchers a curated scientific perspective on emerging research across bladder cancer, genitourinary oncology, and adjacent areas of cancer science.
Led by Dr. Faltas, a genitourinary medical oncologist and physician-scientist at Weill Cornell Medicine, each edition highlights notable studies and provides commentary on their scientific insight, clinical relevance, and broader implications for GU oncology research and care.
Issue 01 | June 2026 features four studies spanning high-risk NMIBC, cisplatin-ineligible MIBC, PSMA-targeted radioligand therapy, and tumor evolution in metastatic cancer.
Featured in this month’s issue:
Sasanlimab plus BCG Induction and Maintenance Prolongs EFS in BCG-Naïve, High-Risk NMIBC: CREST
READ MORE
cCR in 39% of Cisplatin-Ineligible MIBC Patients after Sacituzumab Govitecan plus Pembrolizumab: SURE-02
READ MORE
Day-15 PSMA SUV Mean Increase Identifies the mCRPC Subgroup with Greatest PSA-PFS Benefit from Added Lu-PSMA-617: ENZA-P Substudy
READ MORE
TRACERx-PEACE: Met-to Met Seeding Accounts for More Than Half of Metastatic Events in NSCLC, With Chromosomal Instability Enriched in Extrathoracic-Spreading Subclones
READ MORE
|
